{"id":9527,"date":"2025-12-08T09:04:52","date_gmt":"2025-12-08T09:04:52","guid":{"rendered":"https:\/\/www.library.sath.nhs.uk\/research\/?p=9527"},"modified":"2025-12-08T09:05:12","modified_gmt":"2025-12-08T09:05:12","slug":"atezolizumab-induced-thyroiditis-and-immune-checkpoint-inhibitor-ici-type-1-diabetes-mellitus-diagnostic-and-therapeutic-challenges-in-ici-associated-endocrinopathies-2025","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2025\/12\/08\/atezolizumab-induced-thyroiditis-and-immune-checkpoint-inhibitor-ici-type-1-diabetes-mellitus-diagnostic-and-therapeutic-challenges-in-ici-associated-endocrinopathies-2025\/","title":{"rendered":"Atezolizumab-Induced Thyroiditis and Immune Checkpoint Inhibitor (ICI)-Type 1 Diabetes Mellitus: Diagnostic and Therapeutic Challenges in ICI-Associated Endocrinopathies (2025)"},"content":{"rendered":"\n<p><strong>Type of publication:<\/strong><\/p>\n\n\n\n<p>Journal article<\/p>\n\n\n\n<p><strong>Author(s):<\/strong><\/p>\n\n\n\n<p>*Al-Rubaye, Rafal; *Nadeem, Sabha; Soliman, Ahmed Abdulkader Zaki Ali.<\/p>\n\n\n\n<p><strong>Citation:<\/strong><\/p>\n\n\n\n<p>Cureus. 17(10):e94593, 2025 Oct.<\/p>\n\n\n\n<p><strong>Abstract:<\/strong><\/p>\n\n\n\n<p>The rapid evolution and increased application of immune checkpoint inhibitors (ICIs) in the oncology setting have introduced novel diagnostic and therapeutic challenges, particularly in the setting of endocrine immune-related adverse events (irAEs). Thyroid dysfunction is among the most common of these, while ICI-type 1 diabetes mellitus is uncommon and can present abruptly with life-threatening complications. A 76-year-old man with extensive-stage small-cell lung cancer being treated with atezolizumab developed new-onset diabetes, which manifested as diabetic ketoacidosis in connection with immunotherapy-induced thyroiditis. Metabolic instability in this patient was compounded by the inappropriate initiation of thyroid hormone replacement during the thyrotoxic phase of the thyroiditis as a result of misinterpretation of his thyroid function tests (TFTs). The unique clinical course of this patient illustrates the broad and unpredictable spectrum of ICI-related endocrinopathies and highlights the importance of prudent interpretation of TFTs, early recognition of ICI-induced type 1 diabetes mellitus, and close multidisciplinary management of irAEs.<\/p>\n\n\n\n<p><strong>DOI:<\/strong> 10.7759\/cureus.94593<\/p>\n\n\n\n<p><a href=\"https:\/\/libkey.io\/libraries\/1791\/articles\/681730509\/full-text-file\">Link to full-text<\/a> [open access - no password required]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Journal article Author(s): *Al-Rubaye, Rafal; *Nadeem, Sabha; Soliman, Ahmed Abdulkader Zaki Ali. Citation: Cureus. 17(10):e94593, 2025 Oct. Abstract: The rapid evolution and increased application of immune checkpoint inhibitors (ICIs) in the oncology setting have introduced novel diagnostic<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2025\/12\/08\/atezolizumab-induced-thyroiditis-and-immune-checkpoint-inhibitor-ici-type-1-diabetes-mellitus-diagnostic-and-therapeutic-challenges-in-ici-associated-endocrinopathies-2025\/\">Read more <span class=\"screen-reader-text\">Atezolizumab-Induced Thyroiditis and Immune Checkpoint Inhibitor (ICI)-Type 1 Diabetes Mellitus: Diagnostic and Therapeutic Challenges in ICI-Associated Endocrinopathies (2025)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[1001,200],"tags":[1085,989,1002],"class_list":["post-9527","post","type-post","status-publish","format-standard","hentry","category-open-access","category-staff-publication","tag-1085","tag-endocrinology-and-diabetes","tag-gold-open-access"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/9527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=9527"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/9527\/revisions"}],"predecessor-version":[{"id":9529,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/9527\/revisions\/9529"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=9527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=9527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=9527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}